Product Name | YM-08 |
Description |
Hsp70 Inhibitor |
Purity | >99% (HPLC) |
CAS No. | 812647-88-4 |
Molecular Formula | C19H17N3OS2 |
Molecular Weight | 367.49 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO |
Source | Synthetic |
Appearance | Yellow-orange solid |
SMILES | O=C2C(SC(=Cc1ncccc1)N2CC)=C3Sc4ccccc4N3C |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | YM-08 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-122) |
Alternative Names | (2Z,5E)-3-ethyl-5-(3-methyl-1,3-benzothiazol-2-ylidene)-2-(pyridin-2-ylmethylidene)-1,3-thiazolidin-4-one, YM8, YM08 |
Research Areas | Alzheimer's Disease, Apoptosis, Cancer, Cell Signaling, Heat Shock, Neurodegeneration, Neuroscience |
Scientific Background | YM-08 is a blood-brain barrier-permeable derivative of the Hsp70 inhibitor MKT-077. Although slightly less potent in vitro, YM-08 selectively reduces pathogenic tau in brain slices, a capability not observed with its predecessor. Its improved pharmacokinetics and reduced renal retention suggest lower nephrotoxicity, enhancing its therapeutic potential. YM-08’s ability to target tau pathology in the central nervous system positions it as a promising candidate for treating tauopathies such as Alzheimer’s disease and frontotemporal dementia. |
References | 1. Miyata, Y. et al. 2013 ACS Chemical Neuroscience Jun 19;4(6):930-9. doi: 10.1021/cn300210g |
Reviews
There are no reviews yet.